Skip to main content Accessibility help
×
Home
Hostname: page-component-747cfc64b6-7hjq6 Total loading time: 0.201 Render date: 2021-06-13T06:50:48.139Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true }

Intratympanic methylprednisolone as first-line therapy in sudden sensorineural hearing loss: preliminary results from a case–control series

Published online by Cambridge University Press:  02 August 2011

I Dallan
Affiliation:
ENT Unit, Azienda Ospedaliero Universitaria Pisana, Italy
S Fortunato
Affiliation:
ENT Unit, Azienda Ospedaliero Universitaria Pisana, Italy
A P Casani
Affiliation:
ENT Unit, Azienda Ospedaliero Universitaria Pisana, Italy
E Panicucci
Affiliation:
Department of Experimental Pathology, University of Pisa, Italy
S Berrettini
Affiliation:
ENT Unit, Azienda Ospedaliero Universitaria Pisana, Italy
R Lenzi
Affiliation:
ENT Unit, Azienda Ospedaliero Universitaria Pisana, Italy
A Nacci
Affiliation:
ENT Unit, Azienda Ospedaliero Universitaria Pisana, Italy
Corresponding
Get access

Abstract

Background:

Sudden sensorineural hearing loss is a true audiological emergency, and its management is much discussed. Currently, no single therapy has been proven effective according to evidence criteria. Recently, intratympanic application of steroids has been increasingly used in refractory cases; however, it has only rarely been reported as first-line therapy.

Materials and methods:

Twenty consecutive patients with sudden sensorineural hearing loss treated between July 2008 and January 2010 were enrolled in this prospective, case–control study. Ten patients were treated with intratympanic steroids and 10 with systemic ‘shotgun’ therapy (including steroids, pentoxifylline, low molecular weight heparin and vitamin E). The two groups were homogeneous in all respects. Pure tone averages were assessed before and after treatment for both groups.

Results:

There were no statistically significant differences between the two groups.

Conclusion:

Intratympanic steroids seem to offer a valid alternative to systemic therapy, with few risks, in sudden sensorineural hearing loss patients, and we recommend their use as first-line therapy.

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited 2011

Access options

Get access to the full version of this content by using one of the access options below.

References

1Hughes, GB, Freedman, MA, Haberkamp, TJ, Guay, ME. Sudden sensorineural hearing loss. Otolaryngol Clin North Am 1996;29:393405Google ScholarPubMed
2Stokroos, RJ, Albers, FW. The etiology of idiopathic sudden sensorineural hearing loss. A review of the literature. Acta Otorhinolaryngol Belg 1996;50:6976Google ScholarPubMed
3Schreiber, BE, Agrup, C, Haskard, DO, Luxom, LM. Sudden sensorineural hearing loss. Lancet 2010;375:1203–11CrossRefGoogle ScholarPubMed
4Mattox, DE, Simmons, FB. Natural history of sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol 1977;86:463–80CrossRefGoogle ScholarPubMed
5Fetterman, BL, Sauders, JE, Luxford, WN. Prognosis and treatment of sudden sensorineural hearing loss. Am J Otol 1996;17:529–36Google ScholarPubMed
6Rauch, SD. Idiopathic sudden sensorineural hearing loss. N Engl J Med 2008;359:833–40CrossRefGoogle ScholarPubMed
7Conlin, AE, Parnes, LS. Treatment of sudden sensorineural hearing loss. A meta-analysis. Arch Otolaryngol Head Neck Surg 2007;133:582–6CrossRefGoogle ScholarPubMed
8Garcia-Berrocal, JR, Ramirez-Camacho, R, Lobo, D, Trinidad, A, Verdaguer, JM. Adverse effects of glucocorticoid therapy for inner ear disorders. ORL J Otorhinolaryngol Relat Spec 2008;70:271–4CrossRefGoogle ScholarPubMed
9Hong, SM, Park, CH, Lee, JH. Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngol Head Neck Surg 2009;141:579–83CrossRefGoogle ScholarPubMed
10Kara, E, Cetik, F, Tarkan, O, Surmelioglu, O. Modified intratympanic treatment for idiopathic sudden sensorineural hearing loss. Eur Arch Otolaryngol 2010;267:701–7CrossRefGoogle ScholarPubMed
11Dallan, I, De Vito, A, Fattori, B, Casani, AP, Panicucci, E, Berrettini, S et al. Intratympanic methylprednisolone in refractory sudden hearing loss: a 27 patient case-series with univariate and multivariate analysis. Otol Neurotol 2010;31:2530CrossRefGoogle ScholarPubMed
12Wilson, WR, Byl, FM, Laird, N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double blind clinical study. Arch Otolaryngol 1980;106:772–6CrossRefGoogle ScholarPubMed
13Wei, BPC, Muribu, S, O'Leary, S. Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev 2006;(1):CD003998CrossRefGoogle ScholarPubMed
15O'Malley, M, Haynes, DS. Sudden hearing loss. Otolaryngol Clin North Am 2008;41:633–49CrossRefGoogle ScholarPubMed
16Gianoli, GJ, Li, JC. Transtympanic steroids for treatment of sudden hearing loss. Otolaryngol Head Neck Surg 2001;125:142–6CrossRefGoogle ScholarPubMed
17Gloddek, B, Lamm, K, Arnold, W. Pharmacological influence on inner ear endothelial cells in relation to the pathogenesis of sensorineural hearing loss. Adv Otorhinolaryngol 2002;59:7583Google ScholarPubMed
8
Cited by

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Intratympanic methylprednisolone as first-line therapy in sudden sensorineural hearing loss: preliminary results from a case–control series
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Intratympanic methylprednisolone as first-line therapy in sudden sensorineural hearing loss: preliminary results from a case–control series
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Intratympanic methylprednisolone as first-line therapy in sudden sensorineural hearing loss: preliminary results from a case–control series
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *